Podcasts about clinical trials

Vaccines have become one of the most polarizing topics in public health, and frankly, for valid reasons. What we've witnessed over the past few years is an unprecedented breakdown in trust between medical institutions and the public - and that didn't happen in a vacuum.What is the truth about Vaccine Safety and Efficacy? Dr. Roger McFillin sits down with vaccine safety epidemiologist Allison Krug to expose the hidden forces shaping public health, from vaccine safety to the weaponization of fear. They dive deep into the failures of placebo-controlled trials, the truth about natural immunity vs. vaccine-induced immunity, and why good evidence is harder to find than you think. Allison shares what she learned working inside the pharmaceutical industry and reveals how mindset, belief systems, and disconnection from nature and spirituality are fueling today's chronic illness crisis. If you've ever questioned mainstream medicine or want to reclaim your health and autonomy, this conversation will change how you see the world.00:00 Introduction00:05:32 The Danger of Outsourcing Health to "Experts"00:20:45 Mindset, Pain, and the Illusion of Powerlessness00:42:49 Consciousness and the Healing Power Within01:05:32 Germ Theory, Genetics, and the Loss of Agency01:15:47 Awakening to Frequencies: A Spiritual Revolution01:22:23 Dark Spiritual Forces and the Battle for Consciousness01:31:27 How Public Schools Crush Creativity and Independence01:49:05 Medical Paradigm Flaws: What They're Not Telling You01:55:40 Spiritual Emptiness: The Hidden Cost of Modern Culture02:00:12 Radical Responsibility and the Return to Divine LoveAllision Krug WebsiteAllision Krug on XAllison Krug on Megyn Kelly COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities  Dr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

With so many treatment modalities for upper tract urothelial carcinoma, how does new evidence inform optimal care? In this episode of BackTable Tumor Board, urologic oncologist Dr. Nirmish Singla (Johns Hopkins), medical oncologist Dr. Jeannie Hoffman-Censits (Johns Hopkins), and urologic oncologist Dr. Bogdana Schmidt discuss treatment and diagnosis of upper tract urothelial carcinoma (UTUC). --- This podcast is supported by: Ferring Pharmaceuticalshttps://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1 --- SYNPOSIS The discussion covers real-world UTUC cases, highlighting diagnostic challenges, treatment options, and evidence-based management strategies. They address scenarios ranging from localized to advanced UTUC, the role of systemic therapies, perioperative treatments, and the potential for novel approaches with immune checkpoint inhibitors. The episode underscores the evolving landscape of UTUC treatment and the importance of clinical trials and emerging biomarkers in improving patient outcomes. --- TIMESTAMPS 00:00 - Introduction 02:49 - Case Study 1: 66-Year-Old Male with UTUC11:19 - Case Study 2: 73-Year-Old Male with High-Grade Urothelial Carcinoma28:11 - Intravesical Chemotherapy Protocols30:44 - Case Study 3: 57-Year-Old Male with Recurrent Urothelial Cancer41:25 Clinical Trials and Emerging Treatments45:40 Case Study: 55-Year-Old Female with Bulky Lymphadenopathy 56:45 Concluding Remarks and Future Directions --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

In today's episode, we spoke with Jonathan W. Goldman, MD, about the phase 2 LUMINOSITY study (NCT03539536) evaluating telisotuzumab vedotin-tllv (Teliso-V; Emrelis) in patients with c-MET protein–overexpressing, nonsquamous, EGFR wild-type advanced non–small cell lung cancer (NSCLC). Dr Goldman is a professor of medicine in the Division of Hematology/Oncology at UCLA, as well as director of Clinical Trials in Thoracic Oncology, associate director of Early Drug Development, and chair of the University of California Lung Cancer Consortium.

In this episode, Jonathan Norman (Director, Localisation Services, YPrime) and Laura Russell (Senior Vice President, Head of Data and AI Product Development, Advarra) join the podcast to discuss how artificial intelligence is transforming today's clinical operations. They dive deeper into how AI can be used to improve protocol design, drive efficiency in localization processes, and modernize clinical operations to expand access to trials and get treatments to patients sooner. 

Julio G. Martinez-Clark CEO of Bioaccess and President of IAOCR/GCSA Americas is a MedTech trailblazer helping startups accelerate First-in-Human (FIH) clinical trials across Latin America, with over 20 years of experience spanning healthcare, telecom and venture capitalIn this episode, we unpack why more MedTech companies are turning to LATAM for faster, more cost-effective trial execution. Julio shares how his Miami-based CRO helps deliver 58-day CE mark approvals, his experience supporting 100+ device startups and why time, not money, is the most precious currency for early-stage founders. We also touch on trial quality, regulatory strategy and why he believes Latin America will play a defining role in the next era of global MedTech innovationTimestamps:[00:00:47] Why LATAM Is the Next MedTech Trial Hub[00:02:21] The Problem with FIH Trials in the U.S.[00:04:42] How bioaccess® Reduces Approval Timelines by 70%[00:06:01] Strategic Sites, Patient Retention & CRO Infrastructure[00:08:17] Do LATAM Trials Hold Up to FDA & EU Scrutiny?[00:10:43] The Fundraising Pressure Behind Faster Clinical Results[00:12:22] Founder Mistakes in In-House Trial Management[00:14:11] Why LATAM May Overtake Eastern Europe in FIH Volume[00:17:26] Regulatory Standards, UNESCO, and Regional Quality[00:20:10] Julio Outside the Office: Family, Fitness & PodcastingGet in touch with Julio - https://www.linkedin.com/in/juliomartinezclark/Learn more about Bioaccess - https://www.bioaccessla.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

Send us a textDr. Michael Koren joins Kevin Geddings to discuss the motivations of clinical trial veterans who repeatedly participate in medical research studies. Dr. Koren shares that these participants consistently cite the desire to "Make a Difference" as their primary motivation, pushing science and medicine forward for generations to come.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Carol Harvey's powerful journey from experienced nurse to breast cancer survivor offers a unique dual perspective that changes everything.Carol shares her unexpected triple-negative breast cancer diagnosis in September 2020 during the height of COVID restrictions when family couldn't accompany her to treatments. With 35 years of nursing experience and a role teaching future nurses at Liberty University, Carol brought professional knowledge to her patient experience that provided both advantages and surprising challenges.Her decision to join a clinical trial stands as perhaps the most fascinating aspect of this conversation. Despite her medical background, Carol experienced the vulnerability all patients feel when considering experimental treatments. The outcome? Extraordinary monitoring that included multiple echocardiograms, rapid tumor response, and a comprehensive team approach that left her feeling exceptionally well-cared for. "If I were to go through the whole thing again, I would jump into a clinical trial again, 100%," she reflects.Through chemotherapy, surgery, radiation, and even cognitive therapy for "chemo brain," Carol's journey spans numerous departments within Centra Health. Now three years post-treatment with regular follow-ups, she finds herself transformed. "I am such a better person on this side of cancer than I was beforehand," she reveals, describing a deeper faith, greater empathy, and profound perspective shift that turns even "bad hair days" into moments of gratitude. Her powerful closing message resonates for anyone facing difficult circumstances: "I can do hard things." Listen now to experience this remarkable story of professional insight meeting personal transformation.For more content from Centra Health check us out on the following channels.YouTubeFacebookInstagramTwitter

Expanding access to clinical trials in community oncology settings is essential to improving diversity, equity, and inclusion in cancer research. In this episode, CANCER BUZZ speaks with clinical research coordinator, Oluwakemi “Kemi” Oladipupo, MSHS, MPH, BSN, RN, CCRP, whose cancer center recently participated in a foundational oncology clinical trials course, developed by ACCC and the Association of Clinical Research Professionals (ACRP) to help cancer programs expand availability of trials to traditionally underserved communities. Oladipupo shares how this training prepared their center for the challenges of a growing research program, the progress they've made, and the pivotal role of clinical research coordinators in expanding research programs and improving patient access to clinical trials.   Oluwakemi “Kemi” Oladipupo, MSHS, MPH, BSN, RN, CCRP Clinical Research Coordinator Touro-Cancer Center New Orleans, LA   “We know that diversity is a big point, not only as per new FDA guidance, but [to] ensure that every participant is given an equal opportunity to hear about the study. [Our] approach is not to target a certain group of individuals. Really the approach is to target any individual that looks potentially eligible.” - Oluwakemi “Kemi” Oladipupo   Resources:  Community Oncology Can Close the Gap in Cancer Research Increasing Clinical Trial Accrual Through the Implementation of a Clinical Trials Navigator The Role of the Clinical Trials Navigator — [MINI PODCAST] EP 129 Human-Centered Design: A Possible Solution to Rural Clinical Trial Enrollment

Register free at https://brightu.com to watch the full Healing Revolution stream - Breaking News and Upcoming Segments (0:00) - Microscopy of Bio Sludge (2:04) - Bio Sludge as a Vector for Bioterrorism (4:03) - Details of the Chinese Couple's Case (7:23) - Potential for Bioterrorism and EPA's Role (11:51) - Microscopy of Bio Sludge: Dry Condition (17:54) - Microscopy of Bio Sludge: Incubated Condition (39:25) - Moderna Vaccine Approval and RFK Jr. (53:26) - Elon Musk's Criticism of Trump's Bill (1:07:07) - Ukraine War and Financial Corruption (1:12:41) - AI and Humanity's Future (1:17:40) - Self-Awareness in Life Forms (1:20:40) - Artificial Intelligence and Self-Awareness (1:27:51) - The Potential Dangers of AI (1:32:30) - AI's Impact on Infrastructure and Society (1:37:07) - The Role of Light in Healing (1:46:09) - The Healing Revolution Docu Series (1:47:06) - The Importance of Combining Therapies (1:50:03) - The Role of Light in Activating Nutrients (1:51:34) - The Impact of Light on Cancer Treatment (2:33:08) - The Role of Light in Detoxification (2:35:26) - LED vs. Incandescent/Halogen Bulbs (2:36:33) - Wavelengths and Their Therapeutic Benefits (2:38:13) - Dual LED Technology and Natural Intelligence (2:39:45) - Practical Applications and Humanitarian Efforts (2:42:09) - Healing Revolution Course and Additional Resources (2:45:53) - Long COVID Study and Remission Rates (2:47:42) - Final Thoughts and Call to Action (2:50:30) - Health Ranger's Preparedness Tips (2:51:47) - Iodine Supplements and Their Benefits (2:56:14) - Conclusion and Final Remarks (2:58:12) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Today's guest is Xiong Liu, Director of Data Science and AI at Novartis. Xiong returns to the platform in a special episode brought to you by Medable to explore the evolving role of AI in modernizing clinical trials. Their conversation covers how life sciences teams are leveraging AI to streamline data workflows, accelerate study readiness, and maintain regulatory compliance in both decentralized and traditional models. Throughout the episode, Xiong shares insights into the growing importance of integrating structured and unstructured data across trial systems — from clinical notes to imaging and lab results. This episode is sponsored by Medable. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

Europe Notified Body survey report - 31 October 2024 - What is the main Surprise: https://health.ec.europa.eu/document/download/59b9d90e-be42-4895-9f6f-bec35138bb0a_en?filename=md_nb_survey_certifications_applications_en.pdf The MIR form has been updated - Version 7.3.1 - Don't use previous versions: https://health.ec.europa.eu/medical-devices-sector/new-regulations/guidance-mdcg-endorsed-documents-and-other-guidance/pmsv-reporting-forms_en   UK: UK MIR and FSCA - Change is in the AIR: https://www.gov.uk/government/publications/more-implementation/gb-mir-and-fsca-schema-implementation-guide UK MDR 2002 is dying - Long life to UK MDR 2025: https://www.legislation.gov.uk/ukdsi/2025/9780348269529 : Real-World Data or Clinical Trial or Both?- This is the question: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions     Training EU MDR Green Belt June 2025 - June 23rd, June 27th: https://school.easymedicaldevice.com/course/gb34/ eTraining on Vigilance and Audit preparation - Self-paced: https://school.easymedicaldevice.com/emd-course   ROW USA Q-Sub update  - New electronic template: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-medical-device-q-submissions   Brazil: SIUD or UDI in Brazil - Manual of Use in Portuguese: https://www.gov.br/anvisa/pt-br/assuntos/produtosparasaude/temas-em-destaque/arquivos/manual_siud_v01.pdf   Saudi Arabia: Series of Webinar - June is a Busy month in Saudi Arabia: 16 June 2025 Companion Diagnostic Regulatory Requirements: https://www.sfda.gov.sa/en/workshop/3540492 17 June 2025 Saudi Unique Device Identification (SAUDI-DI): https://www.sfda.gov.sa/en/workshop/3540493 19 June 2025 Artificial Intelligence and Machine Learning: https://www.sfda.gov.sa/en/workshop/3540495 23 June 2025 Digital Health Medical Devices regulatory approach: https://www.sfda.gov.sa/en/workshop/3540496 24 June 2025 Medical Devices Risk Classification: https://www.sfda.gov.sa/en/workshop/3540497 Saudi In-house Devices - Not like EU: https://www.sfda.gov.sa/sites/default/files/2025-05/MDS-G022En.pdf   Turkey: In Turkey, Economic Operators are Liable - Even after discontinuation or temporary stop of supply: https://titck.gov.tr/duyuru/tibbi-cihazlarin-tedarikinin-kesintiye-ugramasi-veya-durdurulmasi-sona-ermesi-durumunda-i-ktisadi-i-sletmecilerin-yukumlulukleri-hakkinda-duyuru-21052025113350   PODCAST: Podcast Nostalgia - What happened in May 2025 Episode 334 - What is the new UK Post-Market Surveillance Requirements? With Claire Dyson: https://podcast.easymedicaldevice.com/334-2/ Episode 335 - When is Regulatory Affairs needed during Design? With Aouda Ouzza: https://podcast.easymedicaldevice.com/335-2/ Episode 336 - is EHDS dangerous for Medical Device Manufacturers? With Cecile van der Heijden: https://podcast.easymedicaldevice.com/336-2/ Episode 337 - How Deepeye Medical overcame the AI Act? With Carmen Bellebna; https://podcast.easymedicaldevice.com/337-2/ Episode 338 - Trapped or Strategic? Changing Notified Bodies During MDR transition: https://podcast.easymedicaldevice.com/338-2/  

Julio Martinez-Clark teamed up with his cardiologist brother and other doctors to help speed up the clinical trials part of the process. Julio's team at bioaccess® is moving medicine forward quicker by helping startups and researchers get the data from clinical trials in other countries. Advancements can now come to market quicker while also helping suffering people in countries that do not have the means to afford the proper medical care. This saves time, money, and people.Julio Martinez-Clark is the co-founder and CEO of bioaccess®. Julio believes Latin America is an untapped destination for Medtech clinical research. Since 2010, Julio has supported +100 Medtech in operationalizing successful clinical trials in several countries in Latin America. Julio was the chairman of the board of the Association for the Advancement of Clinical Research in Colombia (AVANZAR). Julio writes a column at Med Device Online, where his articles have been "Featured Editorials" on several occasions. Julio hosts the LATAM Medtech Leaders podcast, interviewing Medtech leaders who have succeeded in Latin America.Julio has a wealth of experience in various fields, including serving as an advisor to the CEO of Amavita Heart and Vascular Health™, the most extensive cardiovascular practice in South Florida, an advisor to government agencies in Colombia looking to position the country as a clinical trial destination, and a mentor to startups at Macondo Labs, a top incubator in Colombia.Learn more at www.bioaccessla.com and connect with Julio on Linkedin @juliomartinezclark Visit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys

Send us a textDr. Nikhil Kapila joins Dr. Michael Koren on this live MedEvidence! presentation. Dr. Kapila, a liver disease specialist, explains why we can't live without our liver. The doctors review what the liver does, what can cause damage to the liver, and what can go wrong when the liver suffers damage. They also discuss the importance of early testing, treatment options for some conditions, and the importance of clinical research in pushing liver health forward.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Rafael Fonseca is a distinguished Haematologist at Mayo Clinic, specialising in multiple myeloma and related plasma cell disorders. He earned his medical degree at Universidad Anáhuac in Mexico, and went on to complete his residency in Internal Medicine at the University of Miami, Florida, USA followed by a Hematology and Oncology fellowship at Mayo Clinic in Rochester, Minnesota, USA.     Timestamps  01:44 – Quickfire questions  07:25 – CAR-T cell therapy  10:48 – Anti-CD38 antibodies  13:31 – Minimal residual disease  14:30 – Bispecific antibodies  15:31 – Antibody-drug conjugates  19:04 – ASCO 2025  21:24 – Genetic discoveries  26:28 – Fonseca's three wishes 

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join Jamal Khan and Jennifer Johnson as they explore the evolving landscape of AI in healthcare, focusing on its applications, ethical considerations, data privacy, and the role of Chief AI Officers. This discussion highlights the importance of governance, patient consent, and the potential of AI to improve healthcare workflows while addressing data security challenges. Learn about how to implement AI responsibly for better healthcare outcomes and operational excellence.  Speakers: Jamal Khan, Chief Growth and Innovation Officer at Connection Jennifer Johnson, Director of Healthcare Strategy and Business Development at Connection   Show Notes: 00:00 The Evolution of AI in Healthcare 03:04 Ethics and Governance in AI Applications 06:05 Data Privacy and Security Concerns 08:49 The Role of Chief AI Officers 12:07 Patient Consent and Data Usage 14:54 AI's Impact on Healthcare Workflows 18:00 Computational Power in Health Data Analysis 20:47 Virtual Assistants in Healthcare 24:00 Clinical Trials vs. Drug Discovery 26:55 The Future of Patient Data Management 28:11 AI Adoption in Insurance Companies 33:05 Transparency and Explainability in AI 37:28 AI Use Cases in Healthcare 44:10 Cloud vs On-Prem AI Solutions 49:23 Data Orchestration in Healthcare   For more information on AI services for healthcare, visit https://www.cnxnhelix.com/healthcare.     

We welcome Karla Childers to AI Uncovered. Karla is a long-standing leader in bioethics and data transparency in the pharmaceutical industry. As part of the Office of the Chief Medical Officer at Johnson & Johnson, she brings deep expertise in navigating the ethical implications of emerging technologies, especially artificial intelligence, in medicine and drug development.In this episode, Tim and Karla explore the intersection of AI, bioethics and patient-centered development. They discuss how existing ethical frameworks are being challenged by the rise of generative AI and why maintaining human oversight is critical—especially in high-context areas like clinical trial design, consent and medical communications. Karla also shares her views on the future of data privacy, the complexity of patient agency and how to avoid losing trust in the race for efficiency.Karla is a strong advocate for using innovation responsibly. From her work with internal bioethics committees to her perspective on evolving regulatory expectations, she offers bold insights into how the industry can modernize without compromising ethics or equity.Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries. With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product.

In the latest collaboration between ACRO and TransCelerate BioPharma, Cris McDavid (Senior Director, Global Clinical Operations, Parexel) and Tashan Mistree (Senior Director, Business Operations, Office of Chief Medical Officer, GSK) join this week's episode to discuss the impact of ICH E6(R3) from their different vantage points in the clinical research industry. They dive deeper into their experiences implementing the new guidance at their respective companies, the new opportunities that R3 has created in the partnership between CROs and sponsors, and how they envision the future state of R3 once industry has fully embraced the guidance. FIND ACRO & TRANSCELERATE'S ICH E6(R3) TOOLS & RESOURCES HERE: https://www.acrohealth.org/initiatives-hub/interpreting-ich-e6r3/ 

In this powerful and emotional episode, we welcome special guest Jen, who bravely shares the story of her husband Mike's eight-year battle with brain cancer—a journey marked by resilience, heartbreak, and unwavering love.Through years of surgeries, research, second opinions, and clinical trials, Jen and Mike did everything they could to fight the disease. In the midst of the uncertainty, they were gifted with a beautiful daughter, who became a beacon of hope and strength.Eventually, when there options were available exhausted, they made the courageous choice to shift from fighting the disease to fully living the time they had left together. Jen opens up about what it means to love deeply, grieve honestly, and honor someone's life by continuing to move forward.This is a story of grace in the face of pain, and what it means to truly live—even when time is limited.Follow us on IG for more:https://www.instagram.com/spillinitpodcast?igsh=MWM1ZTZncDBiczZ4Mg%3D%3D&utm_source=qrhttps://www.instagram.com/thecortreport?igsh=NWxsaDdkOXRhbm56&utm_source=qrhttps://www.instagram.com/grayed_early?igsh=MWRwZ2VodzRmaHZuNA%3D%3D&utm_source=qrhttps://www.instagram.com/jena0614?igsh=Y2JoanphM2ZzbmFpHave an inspiring story you would like to share? Fill out the following Questionnaire and we will be in touch.Resources:

Join Andrew Warmington, Manufacturing Editor at Citeline, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics. In this episode, recorded live at the European Association for the Study of the Liver Congress (EASL) in Amsterdam, Tom shares invaluable insights into the evolving landscape of hepatology clinical trials and the unique challenges and opportunities shaping the field today. Listen now to stay ahead in the dynamic world of clinical trials.

Send us a textDr. Michael Koren joins Kevin Geddings to discuss how Knowledge is Power - especially when it comes to medicine. The doctor explains how diagnostic tests like high sensitivity C-reactive protein (HSCRP) empower physicians and patients by giving insight into heart attack and stroke risk. Dr. Koren also tells us that even simple things like knowing you are in a research study can improve patient outcomes, and that knowledge is the guiding principle in medicine.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

What if clinical trials could save lives and launch your global medtech career? What happens when you combine cutting-edge medical devices, international clinical trials, and a relentless drive to create real-world impact? Meet Julio M. Clark — CEO of bioaccess® and host of the LatAm MedTech Leaders podcast — who turned a one-man regulatory operation into a pioneering contract research organization transforming healthcare across Latin America. In this episode of Neurocareers: Doing the Impossible!, we explore: How Latin America became a hub for first-in-human clinical trials The unique challenges and opportunities of medical device research in global markets Why AI is revolutionizing everything from informed consent to trial proposals Career pathways for biomedical engineers and clinicians in medtech startups The mindset needed to build impactful ventures from scratch — even after failure Julio shares the entrepreneurial journey behind bioaccess®, the future of medtech clinical trials, and how YOU can contribute to life-saving innovation—even if you're just starting out. Whether you're a neurotech enthusiast, aspiring clinical researcher, or global health innovator—this episode will inspire you to think bigger, act bolder, and, most importantly, choose the right table.

In this episode of It Takes Balls, Dr. Nabil Adra, a medical oncologist at Indiana University Health and leading researcher in testicular cancer care explores everything from recurrence and refractory disease to the latest advancements in treatment and monitoring.Dr. Adra breaks down risk categories that guide treatment - good, intermediate, and poor - and explains how factors like tumor type and blood markers shape decisions about chemo, surgery, or surveillance. He also dives into the science behind relapse and platinum resistance.A major highlight of the episode is the discussion of innovative diagnostic tools like circulating tumor DNA (ctDNA) and microRNA-371. These biomarkers are making it possible to detect microscopic cancer earlier and more accurately, with the goal of reducing overtreatment and improving outcomes.Dr. Adra also shares insights on long-term monitoring, including the reality of late relapse, and emphasizes why annual checkups are crucial - even decades after treatment. For those with relapsed or refractory disease, he offers a hopeful look at cutting-edge therapies including targeted treatments, high-dose chemo, and upcoming CAR-T cell trials.Have a question for a future expert guest? Submit here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-question-submissionWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgEmail Dr. Adra:nadra@iu.eduFollow Steven Crocker: https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Theme song: No Time Like Now - Tom Willner www.tomwillner.com

Saudi Arabia's modern healthcare system, diverse patient population, and research-savvy healthcare professionals make it a great place to conduct clinical trials. To learn more about the clinical trial requirements in Saudi Arabia, I invited Professor Majed Al Jeraisy on the show.   Dr. Al Jeraisy is an Associate Professor of Pharmacy Practice, College of Pharmacy, King Saud Ben Abdulaziz University for Health Sciences and Pediatric Clinical Pharmacy Consultant in King Abdullah Specialized Children Hospital. He was appointed as the chairman of the research office at King Abdullah International Medical Research Center (KAIMRC) in 2007 and was appointed as the Director of Clinical Trial Services in 2018.  Please join me in welcoming Professor Majed Al Jeraisy on the Clinical Trial Podcast. This podcast is brought to you by Slope. Slope drives operational excellence for highly complex, sample-intensive, early-phase clinical trials. The platform transforms chaotic clinical trial supply chains into protocol-specific operational workflows for sponsors, CROs, clinical research sites and labs. Learn more at https://www.slopeclinical.com/ This podcast is brought to you by Florence Healthcare. Florence eliminates chaotic workflows in clinical research operations with remote access and digital workflow platforms. More than 12,000 study sites, sponsors, and CROs in 45 countries trust them to accelerate their operations. To learn more, visit https://florencehc.com 

Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Inato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Today's guest is Shreyas Becker, Head of AI & Data Products, Manufacturing & Supply at Sanofi. Shreyas joins Emerj Managing Editor Matthew DeMello to discuss the practical application of AI in life sciences, focusing on tools that are already improving supply chain resilience and manufacturing efficiency. He explains how AI helps navigate geopolitical disruptions, optimize production workflows, and ensure the reliable delivery of critical medications. The conversation also covers the evolution of AI systems developed during the pandemic and their role in shaping future innovations. For pharma and life sciences professionals, Shreyas provides valuable insights into where AI is delivering impact today and the continuing importance of human expertise in these processes. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! This episode is sponsored by Arkestro. Learn more about Arkestro's upcoming Advisory Council event here. Find out more about sponsored content and how to engage with the Emerj audience at emerj.com/ad1.

Send us a textDr. Michael Koren joins Kevin Geddings to discuss why atrial fibrillation (AFib) receives so much attention in advertising compared to other services hospitals provide. The cardiologist explains the financial incentives for hospitals and device manufacturers behind these marketing campaigns, contrasting them with clinical research, which has the financial and legal incentive to measure accurate data when evaluating the success rate of a particular medication or device. Dr. Koren also discusses a current research study for a new AFib monitoring patch to highlight the difference between objective medical research and profit-driven medical marketing.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The uncertainty surrounding changes at the FDA and other market dynamics is reshaping the global drug development landscape. In this webinar, CRO regulatory leaders will summarize the collective experience of the biotech companies we've spoken to recently. We will explore: • The impact of the FDA leadership changes, staffing cuts, and return to office mandates in reshaping regulatory priorities. • Trends we're observing from biotech sponsors on the decision of whether or not to keep trials in the US. • The broader implications for industry investment, pipeline prioritization strategies, and international responses. This episode is part 1 of 4 in the series “Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials”, featuring insights from Novotech on evolving trends impacting global clinical development. Stay tuned for the next episode, where we'll continue exploring the key forces shaping the future of clinical trials.

Malaikannan Sankarasubbu (Chief Technology & AI Officer, Saama) and Jonathan Shough (Chief Information Officer, Parexel) join this week's episode to discuss how the strategic use of AI technologies is transforming clinical development. They dive deeper into which advancements in generative AI have the potential to improve the clinical trial workflow, the integration of AI and predictive analytics in risk assessment processes, and the importance of strong change management strategies when implementing new AI technologies.

A new clinical trial is underway to test a traditional Pacific healing method for treating post-traumatic stress disorder, or PTSD. The study's co-lead University of Waikato associate professor Sione Vaka spoke to Corin Dann.

What if targeting a single cellular pathway could slow aging and boost immunity? Dr. Joan Mannick, a leading voice in aging science, reveals how mTOR inhibitors may be the future of longevity therapeutics. From her early inspiration to groundbreaking clinical trials, Dr. Mannick explores the role of mTOR in aging, immune response, and antiviral immunity. Learn how selective mTOR inhibition could extend healthspan without compromising muscle mass, improve vaccine response in older adults, and unlock new possibilities in clinical longevity. Learn more about Dr. Joan Mannick: https://www.linkedin.com/in/joan-mannick-8089a614/ - Download Dr. Buck Joffrey's FREE ebook, Living Longer for Busy People: https://ru01tne2.pages.infusionsoft.net/?affiliate=0 Book a FREE longevity coaching consultation with Dr. Buck Joffrey: https://coaching.longevityroadmap.com/

Dr. Doug Thamm discusses the development and use of Tanovea, a drug for treating lymphoma in dogs. He explains the drug's origins, initially researched as a human cancer therapeutic in collaboration with Gilead Sciences, and its transition to veterinary use.   Dr. Thamm provides insights into Tanovea's application, dosage, and effectiveness compared to the CHOP protocol, as well as its potential side effects and other possible uses in different cancer types like multiple myeloma. The episode also delves into related immunotherapy research and personal reflections from Dr. Thamm, a double cancer survivor, on his career choice in veterinary oncology. Your Voice Matters!   If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Videos:  https://www.youtube.com/watch?v=G0iRyKshzq8  Related Links:  Our article on lymphoma: https://www.dogcancer.com/articles/types-of-dog-cancer/lymphoma-in-dogs/  Our article on Tanovea: https://www.dogcancer.com/articles/drugs/tanovea-rabacfosadine-chemotherapy/  Get the facts on dog cancer remission: https://www.dogcancer.com/articles/stats-and-facts/dog-cancer-remission/  Chapters:  00:00 Introduction  00:13 Interview with Dr. Doug Thamm  00:26 The Early Involvement with Tanovea  00:41 Challenges and Discoveries in Drug Development  02:16 Transition from Human to Veterinary Use  02:48 Clinical Trials and Dosage Experiments  06:45 FDA Approval and Practical Use  08:05 Comparing Tanovea and CHOP Protocol  15:23 Exploring Alternative Treatments: Laverdia  18:43 Off-Label Uses and Future Research  23:46 Exploring Tanovea's Effectiveness in Blood Cancers  25:14 Cost Comparison: Tanovea vs. CHOP  26:15 Side Effects of Tanovea  28:47 Pulmonary Fibrosis and Breed-Specific Risks  32:52 Personal Cancer Journeys: Dr. Doug and His Wife  38:23 Debunking Myths About Dog Cancer Treatment  42:24 The Future of Cancer Treatment: Immunotherapy  45:23 Conclusion and Resources    Get to know Dr. Doug Thamm: https://www.dogcancer.com/people/doug-Thammm-v-m-d-diplomate-acvim-oncology/   For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/   Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in Manchester and Cambridge to spearheading transformative cancer treatments at AstraZeneca. She discusses pivotal moments in her career, AstraZeneca's vision for eliminating cancer as a cause of death, the role of patient stories in motivating R&D efforts, and the integration of emerging technologies like AI and digital health tools.  With a focus on collaboration and continuous learning, Susan provides insights into how successful oncology drugs are developed and the importance of equitable representation in clinical trials. Stay tuned for an engaging conversation that highlights the future of personalized cancer therapies and the collaborative efforts driving innovations in oncology.Chapter Summaries;00:00 Introduction and Guest Welcome00:27 Susan Galbraith's Career Journey02:37 Defining Success in Oncology R&D05:01 Early Phase Drug Development07:09 Digital Health and Patient Experience12:37 Global Collaboration and Innovation15:05 AI and Future of Oncology28:08 Diversity and Inclusion in Clinical Trials33:46 Mentorship and Career Advice37:45 Challenges and Future Outlook in Oncology42:06 Closing Remarks and Call to Action Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Susan Gabraith;LinkedIn: https://www.linkedin.com/in/susan-galbraith-584a195/?originalSubdomain=uk Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

What does it take to challenge the deadliest brain tumors with sound waves? How do you scale a medtech startup into a multinational clinical company? And what advice can a top neuro-oncology innovator offer to those hoping to follow a similar path? Welcome to Neurocareers: Doing the Impossible! — The podcast where we explore the extraordinary journeys of those advancing the future of neuroscience and neurotechnology. I'm your host, Dr. Milena Korostenskaja. Today we're speaking with Dr. Michael Canney, the Chief Scientific Officer at Carthera, a clinical-stage medtech company revolutionizing brain therapy through therapeutic ultrasound. With over 15 years of experience in MedTech innovation, Dr. Canney specializes in glioblastoma, neurodegenerative diseases, and therapeutic ultrasound drug delivery. He's currently leading the SONOBIRD Phase 3 clinical trial across 40 sites in the U.S. and Europe, pushing the boundaries of what's possible in treating recurrent glioblastoma. Michael's career spans everything from FDA regulatory strategy to high-impact academic collaborations. He's co-authored over 50 peer-reviewed papers in top-tier journals and 14 patent families. But what truly drives him is improving patient outcomes and bringing hope to some of the most challenging areas in brain health. Whether you're curious about clinical trials, neuro-oncology innovations, or carving out your own career in medtech, this conversation is packed with insight and inspiration. Let's dive in! Chapters: 00:00:01 - Revolutionizing Brain Therapy with Ultrasound, Introducing Dr. Michael Canney 00:04:49 - Advancements in Ultrasound for Drug Delivery 00:10:15 - Innovative Ultrasound for Drug Delivery 00:13:49 - Innovative Ultrasound Approach for Tumor Treatment 00:16:02 - Understanding Blood-Brain Barrier Disruption 00:19:28 - Device Overview and Design Features 00:21:32 - Ultrasound Technology for Tumor Treatment 00:24:15 - Device Implantation in Cancer Treatment 00:28:34 - Challenges in Glioblastoma Treatment Trials 00:31:46 - Dr. Michael Canney's Journey into Ultrasound Research 00:36:15 - Starting a Postdoc Journey 00:39:20 - Career Development in Neuroscience 00:43:31 - Building a Startup Team 00:47:38 - Hiring for Clinical Application Specialists 00:52:16 - Growth of Careers in Neurotechnology 00:54:26 - Using AI in Clinical Trials 00:57:13 - Challenges in Medical Device Approval 00:59:41 - Overcoming Challenges in Medical Innovations 01:02:20 - Clinical Trials and Company Information About the Podcast Guest: Michael Canney, Ph.D., is Chief Scientific Officer at Carthera, a clinical-stage medtech company advancing brain therapy through innovative ultrasound-based devices. A co-author of more than 50 peer-reviewed articles, he specializes in neuro-oncology, glioblastoma and neurodegenerative diseases. At Carthera, he is responsible for leading scientific collaborations with academic institutions, organizing U.S. clinical trials and more. Connect with Dr. Canney on LinkedIn: https://www.linkedin.com/in/michael-canney-ph-d-42457b5/ Learn more about Carthera: https://carthera.eu/ Get familiar with the Sonobird clinical trial: https://sonobird.eu/ About the Podcast Host: The Neurocareers podcast is brought to you by The Institute of Neuroapproaches (https://www.neuroapproaches.org/) and its founder, Milena Korostenskaja, Ph.D. (Dr. K), a career coach for people in neuroscience and neurotechnologies. As a professional coach with a background in neurotech and Brain-Computer Interfaces, Dr. K understands the unique challenges and opportunities job applicants face in this field and can provide personalized coaching and support to help you succeed. Here's what you'll get with one-on-one coaching sessions from Dr. K: Identification and pursuit of career goals Guidance on job search strategies, resume, and cover letter development Neurotech / neuroscience job interview preparation and practice Networking strategies to connect with professionals in the field of neuroscience and neurotechnologies Ongoing support and guidance to help you stay on track and achieve your goals You can always schedule a free neurocareer consultation/coaching session with Dr. K at https://neuroapproaches.as.me/free-neurocareer-consultation Subscribe to our Nerocareers Newsletter to stay on top of all our cool neurocareers news at updates https://www.neuroapproaches.org/neurocareers-news  

Inato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

In this episode, Mathew Paruthickal — Global Head of Data Architecture, Utilization, and AI Engineering at Sanofi — joins Emerj Editorial Director Matthew DeMello to explore how AI is reshaping clinical trial operations at scale. He shares how Sanofi is leveraging advanced data strategies to address longstanding bottlenecks in trial design, safety signal detection, and site performance prediction. Mathew outlines the architectural and operational shifts required to move from isolated AI pilots to enterprise-wide transformation. From document intelligence to real-time data orchestration, he details how Sanofi is building integrated, compliant systems that support faster, more informed decision-making across teams and therapeutic areas. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! This episode is sponsored by Medable. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

In this episode of Alter Everything, we chat with Patrick Leung, CTO of Faro Health, about the innovative ways his company is using generative AI to revolutionize the clinical trial process. They discuss handling unstructured data, insights generated by AI to optimize trials, and significant cost savings in the pharmaceutical space! Not sure what a clinical trial is? Fear not! Patrick explains the structure of clinical trials, Faro Health's AI-driven enhancements in medical writing, and the importance of data extraction and analysis.Panelists: Patrick Leung, Chief Technical Officer @ Faro Health - LinkedInMegan Bowers, Sr. Content Manager @ Alteryx - @MeganBowers, LinkedInShow notes: Faro HealthAlteryx's Generative AI for AnalyticsClinicaltrials.gov Interested in sharing your feedback with the Alter Everything team? Take our feedback survey here!This episode was produced by Megan Bowers, Mike Cusic, and Matt Rotundo. Special thanks to Andy Uttley for the theme music and Mike Cusic for the for our album artwork.

Vitamin D recommendations in 1941 began this debate. Over the years, updated guidelines have continued to spark controversy and debate in the field of vitamin D research.In this episode of Daily Value, we look at the recent “Vitamin D-ilemma” reinvigorated by the Endocrine Society's updated 2024 guidelines. These new recommendations have dialed back routine testing and supplementation targets, igniting pushback from leading researchers who argue we might be overlooking significant health benefits (including reduced risks for 8 out of the top 10 leading causes of death). Join us as we Look at the evolving science behind vitamin D, why randomized trials and observational studies seem to tell different stories, and how you can practically navigate these conflicting recommendations to optimize your own health.00:00 Introduction: The Vitamin D Controversy01:00 Historical Guidelines and Shifts01:54 The 2011 Guidelines and Their Impact03:57 The 2024 Update: A New Debate06:13 Understanding Vitamin D's Role in the Body07:29 Clinical Trials vs. Observational Studies09:13 Health Benefits of Higher Vitamin D Levels11:58 Challenges in Vitamin D Research15:56 Practical Recommendations for Optimal Vitamin D19:32 Conclusion: Striving for Optimal HealthPMID: 39861407PMID: 38828961PMID: 37004709PMID: 30992519Support the show

Send us a textDoctor Carolyn Tran joins Neurologist Steven Toenjes to discuss migraines. Migraine is a complex brain disease affecting one in five women and one in ten men, with treatments ranging from traditional medications to cutting-edge therapies targeting specific pathways in the brain. The doctors talk about the causes - or lack thereof, the lack of treatment, and common misconceptions about what headaches should be classified as migraines. Dr. Toenjes explains the phases of migraine, including prodrome, aura, pain, and postdrome. Then the two doctors explore many treatment options, discussing the uses, benefits, and drawbacks of each class of treatment.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today is Clinical Trials Awareness Day, making it the perfect time to spotlight a powerful conversation about access, equity, and the future of cancer research. Host Melissa Berry is joined by Dr. Sara Horton, Strategic Clinical Trials Access and Partnerships Lead at Quantum Leap Healthcare to have an insightful and empowering conversation about clinical trials. Dr. Horton is deeply committed to improving access to clinical trials and ensuring diversity in cancer research—an essential step toward creating treatments that truly work for everyone. In this episode, we explore why representation matters in clinical trials, what barriers still exist, and how her work is helping to break them down. We also discuss the groundbreaking Wisdom Study, how to find and join clinical trials, and how they can be a vital part of improving treatment options. Overall, we talk about the importance of clinical trials and why they're so essential—not only to advance research, but also to getting an upgrade to your own care.

How can pediatric and adult urologists team up to tackle complex cancer cases? In this episode of the BackTable Urology, host Dr. Amanda Buchanan, Division Chief of Pediatric Urology at the University of Kentucky, is joined by her colleagues Dr. Patrick Hensley, an adult urologic oncologist, and Dave Rodeberg, Division Chief of Pediatric Surgery. Their discussion centers around the importance of professional collaboration in urologic oncology care in order to improve patient outcomes.---SYNPOSISThe urologists discuss topics such as the experiences and benefits of interdisciplinary collaboration in complex cases and the role of pediatric urologists in treating adolescent and young adult patients. They also provide insights into the Children's Oncology Group (COG) studies and their intersections with adult oncology research. The episode concludes with practical advice for other institutions aiming to improve collaborative efforts between pediatric and adult urology departments.---TIMESTAMPS00:00 - Introduction02:35 - Challenges and Lessons in Multidisciplinary Collaboration08:24 - Pediatric vs. Adult Urologic Oncology11:07- Clinical Trials and Research Collaborations12:49 - Navigating Oncology Groups for Children and Adults19:06 - Collaborative Models in Kidney Cancer Care22:18 - Benefits and Challenges of Collaboration35:24 - Final Thoughts and Recommendations---RESOURCESSociety of Urologic Oncology:https://suonet.org/home.aspxChildren's Oncology Grouphttps://www.childrensoncologygroup.org/

On October 29-30, 2024, the ACCC Community Oncology Research Institute (ACORI) hosted the Community Oncology Inclusive Clinical Trial Design Summit in Arlington, VA. The event brought together stakeholders including academic and community cancer center practitioners and researchers, advocacy organizations, government agencies, and industry partners to discuss strategies to increase patient access to clinical trials in the community setting. Five priority areas were identified that characterize actionable strategies to promote fair and accessible clinical trial design that is representative of all patients with cancer: strengthening the clinical trial workforce, optimizing trial design, engaging communities outside of clinical trial interactions, decentralizing clinical trials, and leveraging artificial intelligence/digital health tools for increased access and efficiency.   ACCC is committed to providing support in these priority areas to increase representative participation and opportunities in clinical trials for oncology patients across the US. In this episode of CANCER BUZZ, Kimberly Demirhan, MBA, BSN, RN, assistant director of education programs at ACCC, discusses the 5 priority areas identified at the ACORI Summit and ways to transform how we think about access to trials, especially leveraging AI and digital tools to do so.   “We looked at optimizing trial design to reflect real world patient populations ... assessing eligibility criteria to make it more reflective of the patient populations that we see out in the community.”   “[We suggest] simplifying protocols so we're not accidentally eliminating patients [due to] benign factors, and then really engaging our community providers early on in the design process.”   “It's a really important time to be addressing [AI] and looking at the opportunities we have to transform the way we think about clinical trials, how we think about the delivery and access to them.” – Kimberly Demirhan   Kimberly Demirhan, MBA, BSN, RN Assistant Director, Education Programs Association of Cancer Care Centers   Resources: 2024 ACORI Summit Just ASK: Increasing Diversity in Cancer Clinical Research Bringing Cancer Research to the Community: Strategic Approaches to Representative Oncology Clinical Trial Design  

On this episode, Tania Simoncelli (Vice President, Translational Impact and Engagement, Chan Zuckerberg Initiative) and Nasha Fitter (Co-founder & CBO, Citizen Health and Co-founder & CEO, FOXG1 Research Foundation) join forces to discuss how rare disease patient advocacy has transformed over time and how the biopharmaceutical industry should adapt to better meet the needs of today's patients. They dive deeper into the evolution of rare disease patient advocacy groups, why industry must move beyond the hyperfocus on “blockbuster drugs” to make progress in rare disease research, and how advancements in rare disease treatments can benefit the clinical research ecosystem for all.

What if the very tools we rely on to detect breast cancer were putting us at risk? In this eye-opening episode, I sit down with Dr. John Klock, a visionary physician and medical imaging innovator, to expose the truth behind traditional screening methods and reveal a safer, more effective alternative: QT Ultrasound.Dr. Klock shares his incredible journey—from personal diagnosis to pioneering a breakthrough technology that's transforming breast imaging. Together, they unpack the challenges of disrupting an entrenched system, the common misconceptions around FDA clearance vs. approval, and the critical role of metabolic health in breast cancer risk.This episode is packed with life-changing insights about QT technology, the future of screening, and why informed decision-making is every woman's right. If you've ever questioned the safety or necessity of mammography, this conversation is a must-listen.Dr. John Klock is a physician, scientist, and the founder of QT Imaging. With a decades-long career in medical innovation, Dr. Klock is leading the charge to bring safer, radiation-free, high-resolution breast imaging to women across the world. His mission: to change the standard of care in breast health. In This Episode, You Will Learn:Why current imaging methods may be doing more harm than goodHow QT Ultrasound works—and why it's a game changerWhat it means that mammography was never formally FDA-clearedWhy metabolic health is at the center of breast cancer preventionWho qualifies for QT Imaging and how often you actually need to screen✨ This episode is an invitation to reclaim your health with confidence and clarity.If this episode resonated with you, please follow, rate, and leave a review on your favorite podcast platform. And most importantly—share it with a woman you love. This information could change, or even save, her life.

We are joined by Carole Bakhos and Candice Huber this week to talk all things human clinical trials! Candice's family is our first to go through the clinical trial process. We talk all about her experience, what tips you need to know and what's next for all of you. Don't miss out on this crucial […]